Sanofi in talks to sell generics unit for €1.9bn
19-04-2018
Seattle Genetics to acquire biotech company for $614m
02-02-2018
Celgene reveals plans to acquire Juno for $9bn
23-01-2018
Sanofi to buy Bioverativ for $11.6bn
23-01-2018
designer491 / iStockphoto.com
Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Sanofi, Ablynx, pharmaceutical merger, mergers and acquisitions, blood disorder, nanobody, biotech medicine, caplacizumab, thrombotic thrombocytopenic
